Following known facts that the excess ROS stimulate tyrosine kinases to activate NRF2 and that in many carcinomas, including pancreatic carcinoma, there is an overexpression of various tyrosine kinase receptors and their ligands, docking studies identified family of tyrosine kinase receptors as a possible important drug target for tested coumarin derivatives and their corresponding palladium(II) complexes. The gene discussed is NTRK1; the disease is exocrine pancreatic carcinoma.